Inspire Medical Systems, Inc. (INSP) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High gross margin ⢠Elevated operating expense INSP combines a rockâsolid balance sheet, very high gross margins and strong FCF but delivers only modest ROIC/ROE and compressed operating margins amid rising inventory and elevated valuation.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Support holding near $92 ⢠Failed post-rally momentum Support Level: $92.00 Resistance Level: $98â$99 INSP is in a short-term downtrend over the last month, losing momentum from a mid-December spike above $140 to trade around a support area near $92 with resistance near $98â$99.
Sentiment & News
Key News Insights: ⢠Lawsuits filed ⢠32% stock drop ⢠Clinical progress Inspire faces multiple securities class actions after a 32% stock plunge tied to alleged concealed Medicare billing software failures and inventory glut despite positive Inspire V clinical/reimbursement news and looming Jan 5, 2026 lead-plaintiff deadlines.
AI Summary
INSP is no longer just a growth-through-adoption storyâits durable high-margin franchise is now balanced by meaningful near-term cashâflow and credibility risk from a sharp inventory build, multiple class actions tied to alleged billing/software issues, and reimbursement/site economics pressures that can compress multiples if not resolved. Investors should wait for sequential evidence of inventory normalization without writeâdowns, rising Inspire V-driven ASP/mix and EBITDA margins, and shrinking legal provisions before reârating the stock.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |